Why the study?
Bioprosthetic valve failure with transcatheter heart valves in patients with intermediate surgical risk had not been reported.
Does the S3 transcatheter heart valve system reduce bioprosthetic valve failure or mortality compared to the XT system in intermediate-risk patients?
Does the S3 transcatheter heart valve system reduce bioprosthetic valve failure or mortality compared to the XT system in intermediate-risk patients?
In intermediate-risk patients, the S3 transcatheter heart valve system showed similar bioprosthetic valve failure rates but lower mortality and neurological events compared to the XT system at 2 years.
Answers are grounded in this paper and cite their sources.
May reduce death/neurological events versus XT without BVF difference; leaves open need for randomized confirmation in intermediate-risk TAVR.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Eid‐Lidt et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: